Susan E Bates
Columbia University · Yale University Cancer Center LAO · National Cancer Institute (NCI)
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
9
all conditions, ClinicalTrials.gov
NIH grants tied to them
7
4 more share only the name and are not shown
Trial papers
44
PubMed author-name match
Trials
Studies that name Susan E Bates as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:28 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05241249 · Stimulation With Bethanechol in Combination With Gemcitabine and Nab-paclitaxel in Pancreatic AdenocarcinomaSusan E. Bates · recruiting · Pancreas Cancer · principal investigator
- Early Ph1NCT03572283 · Bethanechol Prior to Pancreatic SurgeryColumbia University · completed · Pancreas Cancer · principal investigator
- Ph2NCT03264404 · Azacitidine and Pembrolizumab in Pancreatic CancerSusan E. Bates · completed · Pancreas Cancer · principal investigator
- Ph1NCT02631733 · Liposomal Irinotecan and Veliparib in Treating Patients With Solid TumorsNational Cancer Institute (NCI) · completed · Malignant Solid Neoplasm · principal investigator
- Ph2NCT01679743 · GRN1005 for Brain Metastases From Breast or Lung CancerNational Cancer Institute (NCI) · withdrawn · Breast Cancer, Lung Neoplasms, Breast Neoplasms · principal investigator
- N/ANCT00928382 · A Pilot Study to Explore Serum and Imaging Biomarkers in Patients With Spinal Cord CompressionNational Cancer Institute (NCI) · completed · Cancer, Spine Metastasis · principal investigator
- Ph1NCT00019318 · Depsipeptide in Treating Patients With Solid TumorsNational Cancer Institute (NCI) · completed · Lymphoma · study chair
- Ph2NCT00069160 · Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical CancerNational Cancer Institute (NCI) · completed · Lung Neoplasms, Ovarian Neoplasms, Cervix Neoplasms · principal investigator
- Ph2NCT00019812 · Monoclonal Antibody Plus Chemotherapy in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2National Institutes of Health Clinical Center (CC) · completed · Breast Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:28 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 4 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Clinical Studies to Circumvent Drug ResistanceZIABC010620 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2009 to 2015 · $158,452 awarded in 2015Same name and institution; not confirmed by an ID
- Investigation of the ABC Half-Transporter ABCG2ZIABC010622 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2009 to 2015 · $237,678 awarded in 2015Same name and institution; not confirmed by an ID
- Translational Studies of the Histone Deacetylase Inhibitor RomidepsinZIABC010621 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2009 to 2015 · $1,188,387 awarded in 2015Same name and institution; not confirmed by an ID
- Clinical Studies of Multidrug Resistance ReversalZ01BC010620 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2004 to 2008 · $151,886 awarded in 2008Same name and institution; not confirmed by an ID
- Investigation of the ABC Half-Transporter ABCG2Z01BC010622 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2004 to 2008 · $607,544 awarded in 2008Same name and institution; not confirmed by an ID
- Translational Studies of the Histone Deacetylase Inhibitor RomidepsinZ01BC010621 · NCI · DIVISION OF BASIC SCIENCES - NCI · fiscal years 2004 to 2008 · $759,429 awarded in 2008Same name and institution; not confirmed by an ID
- Lab. and Clinical Studies in Drug Resistance ReversalZ01SC006731 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · fiscal years 1999 to 2004Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:28 UTC. The ranking covers the 200 most relevant of 44 PubMed records, and a shared surname and initials can bring in a namesake. All 44 on PubMed
- Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma.J Clin Oncol · 2009602 citationsRCR 12.9
- Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.Clin Cancer Res · 2002480 citationsRCR 9.4
- Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma.J Clin Oncol · 2020451 citationsRCR 18.9
- 409 citationsRCR 10.0
- 386 citationsRCR 7.6
- Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations.Cancer Res · 1996361 citationsRCR 10.2
- Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma.Clin Cancer Res · 2006208 citationsRCR 4.3
- Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors.J Clin Oncol · 2018152 citationsRCR 4.3
- A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer.Clin Cancer Res · 2011151 citationsRCR 4.5
- Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).Biochem Pharmacol · 2008133 citationsRCR 3.7